Tag Archives: First

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

Here’s how nonprofit hospitals weathered the first half of 2020

The second quarter was an important marker for the healthcare industry as it captured the full weight of the COVID-19 pandemic’s drag on hospital operations. Many of the nation’s largest nonprofit health systems have now disclosed either their second-quarter or six-month results via filings to bondholders. The results are mixed, but many experienced a drop… Read More »

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Print this page HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] Tremfya is the first treatment… Read More »

House panel to hold hearing on VA delay of first EHR go-live

The chair of the House subcommittee charged with legislative oversight of the VA’s Cerner electronic health record implementation is concerned about the agency’s decision to delay the EHR’s initial go-live. “I’m concerned that as we’ve moved closer to the go-live date, we have been told repeatedly that there were no showstoppers in the implementation, that… Read More »